Time-to-treatment failure
FIGURE 5 · Panel Time-to-treatment_failure
Panel Time-to-treatment_failure 是同一 FIGURE 5 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
Silvio Danese, Rupert W Leong, Bruce E Sands, Tony Ma, Colleen Marano, Laurent Peyrin-Biroulet
Aliment Pharmacol Ther 62(5) 483-492
BACKGROUND: Achievement of disease clearance (simultaneous symptomatic remission and histo-endoscopic mucosal improvement [HEMI]) following induction therapy may lead to better long-term outcomes in ulcerative colitis (UC). AIM: To evaluate disease clearance in the phase 3 UNIFI program and its association with long-term outcomes. METHODS: UNIFI comprised randomised, placebo-controlled induction and maintenance studies and a long-term extension, which evaluated intravenous ustekinumab induction (130 mg or ~6 mg/kg) and subcutaneous ustekinumab maintenance therapy (90 mg every 8 or 12 weeks) through 4 years in patients with UC. RESULTS: Disease clearance was achieved by 5.9%, 15.2% and 15.1% of patients 8 weeks after placebo or ustekinumab 130 mg or ~6 mg/kg induction, respectively. Among ustekinumab induction responders randomised to ustekinumab maintenance therapy who did or did not achieve disease clearance 8 weeks after induction, 63.6% and 35.2% (nominal p < 0.001), respectively, achieved clinical remission (Mayo score ≤ 2, no individual subscore > 1) at Week 44. Among ustekinumab induction responders randomised to ustekinumab maintenance therapy who achieved disease clearance, symptomatic remission without HEMI, or neither symptomatic remission nor HEMI 8 weeks after induction, 73.4%, 53.5% (nominal p = 0.002) and 45.1% (nominal p < 0.001), respectively, achieved symptomatic remission (Mayo stool frequency subscore 0/1, rectal bleeding subscore 0) and 58.2%, 46.5% (nominal p = 0.09) and 42.7% (nominal p = 0.05), respectively, achieved Inflammatory Bowel Disease Questionnaire remission (score ≥ 170) at Week 200. CONCLUSIONS: Patients who achieved disease clearance 8 weeks after ustekinumab induction were more likely to be in long-term clinical, symptomatic and quality of life remission with ustekinumab maintenance treatment than patients who did not. TRIAL REGISTRATION: NCT02407236.
1 个 Figure · 1 个 KM 面板
FIGURE 5 Time‐to‐treatment failure event through maintenance Week 220 by induction efficacy categories. Events of interest were defined as UC‐related surgery or hospitalisation, AE of UC, or discontinuation of study agent due to an AE of worsening UC or lack of efficacy. All p ‐values are nominal. AE, adverse event; HEMI, histo‐endoscopic mucosal improvement; UC, ulcerative colitis.
FIGURE 5 · Panel Time-to-treatment_failure
Panel Time-to-treatment_failure 是同一 FIGURE 5 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
这些图片未产生 KM 曲线结果,不在主页面重复展示。